Sergio Huerta, DO
Family Medicine · Las Cruces, NMNPI 1649233008
Payments from drug & device makers
Across 740 payments — averaging $15.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$1K
- Lilly USA, LLC$1K
- AbbVie$1K
- Boehringer Ingelheim$1K
- Merck$646
- plus $4K from 30 others
What the payments were for
- Food & beverage$11,375100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 137 | $1,563 |
| AstraZeneca | 82 | $1,488 |
| Lilly USA, LLC | 98 | $1,271 |
| AbbVie(2 entities) | 66 | $1,135 |
| Boehringer Ingelheim | 55 | $1,044 |
| Merck | 42 | $646 |
| Amgen | 41 | $637 |
| GSK | 34 | $580 |
| Pfizer | 41 | $552 |
| Sanofi-aventis U.S. LLC | 34 | $526 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $429 |
| Johnson & Johnson | 9 | $166 |
| Abbott | 6 | $132 |
| Novartis | 9 | $125 |
| Nalpropion Pharmaceuticals LLC | 8 | $120 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $107 |
| Exact Sciences | 5 | $92 |
| Endogastric Solutions, Inc | 1 | $66 |
| Amarin Pharma, Inc. | 4 | $65 |
| Mylan Specialty L.p. | 4 | $65 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $64 |
| Bayer | 4 | $63 |
| Ultragenyx Pharmaceutical Inc. | 3 | $59 |
| Xeris Pharmaceuticals, Inc. | 3 | $58 |
| Astellas Pharma US Inc | 2 | $47 |
| Radius Health, Inc. | 3 | $47 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| Therapeuticsmd, Inc. | 2 | $37 |
| Nestle Healthcare Nutrition Inc. | 2 | $34 |
| Eisai Inc. | 2 | $33 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| IBSA Pharma Inc. | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Corium, LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,383 in reported general payments places this provider in the 95th percentile of 717 family medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 95 | $114,506 |
| JardianceEmpagliflozin | 66 | $92,568 |
| EliquisApixaban | 41 | $61,013 |
| JanuviaSitagliptin Phosphate | 46 | $53,537 |
| OzempicSemaglutide | 23 | $46,423 |
| RybelsusSemaglutide | 19 | $44,241 |
| XareltoRivaroxaban | 22 | $28,087 |
| TrulicityDulaglutide | 15 | $23,061 |
| TrintellixVortioxetine Hydrobromide | 16 | $20,734 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $19,533 |
| MyrbetriqMirabegron | 12 | $15,604 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $7,262 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $6,712 |
| Atorvastatin Calcium | 417 | $4,579 |
| Levothyroxine Sodium | 410 | $4,294 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $1,488 | $114,50695 claims |
| Boehringer IngelheimJardiance | $1,044 | $92,56866 claims |
| Novo NordiskOzempic, Rybelsus | $1,563 | $90,66342 claims |
| PfizerEliquis | $552 | $61,01341 claims |
| MerckJanuvia | $646 | $53,53746 claims |
| Johnson & JohnsonXarelto | $166 | $28,08722 claims |
| Lilly USA, LLCTrulicity | $1,271 | $23,06115 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $429 | $20,73416 claims |
| Astellas Pharma US IncMyrbetriq | $47 | $15,60412 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $4,294410 claims |
| AbbVieSynthroid | $1,135 | $2,46632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 717 family medicine providers in New Mexico.
Other family medicine in Las Cruces
- Delliah StamppLas Cruces$21K
- Conchita PazLas Cruces$16K
- Brenda CuellarLas Cruces$9K
- Imelda Toledo-NeelyLas Cruces$7K
- Aaron PfauLas Cruces$4K
- Mai OushyLas Cruces$3K
- Jie LuoLas Cruces$3K
- Quito CarrAlbuquerque$10.4M
- Satkirin KhalsaAlbuquerque$5.8M
- Ellen KimAlbuquerque$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.